Navigation Links
DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop
Date:8/26/2009

The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.

Horsham, PA (Vocus) August 26, 2009 -- The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.

Progression-Free Survival (PFS) endpoints are increasingly used for evaluation and approval of oncology drugs. Representatives from FDA, the National Cancer Institute (NCI), and PhRMA will present their perspectives on clinical, radiological, and statistical evaluation of progression-free survival. Sessions will include:

 
  • Clinical Assessment of Progression-Free Survival (PFS)
  • Radiological Evaluation of Progression-Free Survival (PFS)
  • Criteria for Determination of Progression
  • Statistical Evaluation of Progression-Free Survival- Role and Design of Independent Review
  • Statistical Evaluation of Progression-Free Survival--Handling Missing/Censored Observations
  • Statistical Evaluation of Progression-Free Survival--Analysis of Progression-Free Survival
  • Regulatory Considerations
Richard Pazdur, MD, Director, Office of Oncology Drug Products, CDER, FDA, will deliver the keynote address. In addition to his experience as a regulatory expert at FDA, Dr. Pazdur has distinguished himself in clinical and academic oncology. Click here for complete bio.

In addition, two tutorials will be held on October 7:

 
  • Time to Event Analysis for Non-Statisticians
  • Statistical Methods for Interval Censored Data Analyses
Click here to register for the Progression-Free Survival Oncology Workshop.

About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

Contact:
Joe Krasowski
DIA
+1-215-293-5812

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2796274.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
2. Advanced lung cancer patients see improved, progression-free survival
3. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
4. Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia
5. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
6. Survival differences by race most apparent in advanced stages of breast cancer
7. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Mediterranean Diet May Boost Alzheimers Survival
10. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
11. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... the life cycle of pharmaceutical products, garnering increased attention from all stakeholders in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water beverages ... GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature ... event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, has ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance firm ... that will raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd ... school is in a low-income area and has more than 60 2nd and 3rd ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Sequent Medical, Inc. gab heute bekannt, ... eine Studie zur Sicherheit und Wirksamkeit des WEB™-Systems ... Behandlung von rupturierten intrakraniellen Aneurysmen begonnen hat. Prof. ... an der Universitätsklinik Bicètre in Paris ... den ersten Patienten aufgenommen. Im Rahmen ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
Breaking Medicine Technology: